Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)
Hong Kong · Delayed Price · Currency is HKD 14.31
-0.59 (-3.96%)
Sep 11, 2026, 4:08 PM HKT
HKG:2659 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 1,042 | 1,242 | 524.16 | 321.67 |
Short-Term Investments | 2.12 | 1.33 | 1.18 | 2.46 |
Cash & Short-Term Investments | 1,044 | 1,243 | 525.33 | 324.13 |
Cash Growth | 129.80% | 136.60% | 62.08% | - |
Accounts Receivable | 6.91 | 0.1 | 0.14 | 2 |
Other Receivables | - | - | - | 0.04 |
Receivables | 6.91 | 0.1 | 0.14 | 2.04 |
Inventory | 16.78 | 6.25 | 4.72 | 8.07 |
Prepaid Expenses | 0.51 | 0.84 | 0.83 | 1.05 |
Other Current Assets | 143.83 | 113.03 | 134.56 | 30.85 |
Total Current Assets | 1,212 | 1,363 | 665.58 | 366.15 |
Property, Plant & Equipment | 909.18 | 734.26 | 677.13 | 585.42 |
Long-Term Investments | 10.84 | 10.81 | 7.83 | 8.44 |
Other Intangible Assets | 10.95 | 11.69 | 12.32 | 12.57 |
Other Long-Term Assets | 26.62 | 97.06 | 0.41 | 1.31 |
Total Assets | 2,170 | 2,217 | 1,363 | 973.88 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 0.3 | 0.01 | - | - |
Accrued Expenses | 12.44 | 18.33 | 17.63 | 12.14 |
Short-Term Debt | - | - | 29.83 | 20.02 |
Current Portion of Long-Term Debt | 134.08 | 113.96 | 39.74 | 45.09 |
Current Portion of Leases | 1.08 | 1.61 | 1.56 | 0.92 |
Current Income Taxes Payable | 2.06 | 3.47 | 1.16 | 0.98 |
Current Unearned Revenue | 10.17 | 6.41 | 58.37 | 18.36 |
Other Current Liabilities | 154.59 | 186.87 | 47.94 | 49.31 |
Total Current Liabilities | 314.72 | 330.65 | 196.23 | 146.82 |
Long-Term Debt | 287.48 | 198.45 | 132.29 | 44.98 |
Long-Term Leases | 0.52 | 0.98 | 1.84 | 0.1 |
Long-Term Unearned Revenue | 118.38 | 94.92 | 37.03 | 32.83 |
Long-Term Deferred Tax Liabilities | - | - | - | 0.02 |
Total Liabilities | 721.11 | 625.01 | 367.39 | 224.75 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 65.2 | 65.2 | 57.26 | 52.05 |
Additional Paid-In Capital | - | 2,539 | 1,453 | 1,000 |
Retained Earnings | - | -1,063 | -667.66 | -303.23 |
Comprehensive Income & Other | 1,385 | 50.83 | 153.15 | - |
Shareholders' Equity | 1,449 | 1,592 | 995.88 | 749.13 |
Total Liabilities & Equity | 2,170 | 2,217 | 1,363 | 973.88 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 423.17 | 315 | 205.26 | 111.12 |
Net Cash (Debt) | 621.05 | 927.95 | 320.08 | 213.01 |
Net Cash Growth | 198.33% | 189.91% | 50.26% | - |
Net Cash Per Share | 2.01 | 3.20 | 1.20 | 0.84 |
Filing Date Shares Outstanding | 325.89 | 325.98 | 286.3 | 252.96 |
Total Common Shares Outstanding | 325.89 | 325.98 | 286.3 | 252.96 |
Working Capital | 897.52 | 1,033 | 469.35 | 219.32 |
Book Value Per Share | 4.45 | 4.88 | 3.48 | 2.96 |
Tangible Book Value | 1,438 | 1,580 | 983.56 | 736.56 |
Tangible Book Value Per Share | 4.41 | 4.85 | 3.44 | 2.91 |
Buildings | - | 555.79 | 199.13 | 199.13 |
Machinery | - | 196.11 | 174.99 | 164.47 |
Construction In Progress | - | 10.31 | 302.12 | 199.59 |